The 43rd Annual Cowen Health Care Conference with a presentation on March 7, 2023, at 10:30 a.m. ET.
The 44th Annual Raymond James & Associates Institutional Investors Conference with a presentation on March 6, 2023, at 11:35 a.m. ET.
Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industry
SALT LAKE CITY, M...
SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today anno...
Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
“For more than 31 years, Myriad Genetics has worked to be a force for good in the world as we fulfill our mission to advance health and well-being for all. In our inaugural ESG report, we seek to convey our core values as a caring, ethical, and sustainable company committed to continuous improvement,” said Paul J. Diaz, president and CEO, Myriad Genetics. “I want to thank our 2,400 teammates for the progress we have made to date, recognizing we have more work to be done. We are committed to intensifying our ESG focus helping to address the needs of the patients, healthcare providers, stakeholders, and communities we serve.”